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Comparative Study of Immune Regulatory Properties
of Stem Cells Derived from Different Tissues
Mariano Di Trapani,1,* Giulio Bassi,1,* Mario Ricciardi,1 Emanuela Fontana,1,2 Francesco Bifari,1
Luciano Pacelli,1 Luca Giacomello,2 Michela Pozzobon,3 Francois Fe´ron,4,5 Paolo De Coppi,3,6
Piero Anversa,7 Guido Fumagalli,8 Ilaria Decimo,8 Cedric Menard,9,10
Karin Tarte,9,10 and Mauro Krampera1
Allogeneic stem cell (SC)-based therapy is a promising tool for the treatment of a range of human degenerative
and inflammatory diseases. Many reports highlighted the immune modulatory properties of some SC types,
such as mesenchymal stromal cells (MSCs), but a comparative study with SCs of different origin, to assess
whether immune regulation is a general SC property, is still lacking. To this aim, we applied highly standardized
methods employed for MSC characterization to compare the immunological properties of bone marrow-MSCs,
olfactory ectomesenchymal SCs, leptomeningeal SCs, and three different c-Kit-positive SC types, that is, am-
niotic fluid SCs, cardiac SCs, and lung SCs. We found that all the analyzed human SCs share a common pattern
of immunological features, in terms of expression of activation markers ICAM-1, VCAM-1, HLA-ABC, and
HLA-DR, modulatory activity toward purified T, B, and NK cells, lower immunogenicity of inflammatory-
primed SCs as compared to resting SCs, and indoleamine-2,3-dioxygenase-activation as molecular inhibitory
pathways, with some SC type-related peculiarities. Moreover, the SC types analyzed exert an anti-apoptotic
effect toward not-activated immune effector cells (IECs). In addition, we found that the inhibitory behavior is not
a constitutive property of SCs, but is acquired as a consequence of IEC activation, as previously described for
MSCs. Thus, immune regulation is a general property of SCs and the characterization of this phenomenon may
be useful for a proper therapeutic use of SCs.
Introduction
Adult stem cells (SCs) are a promising form of treat-ment for human autoimmune and inflammatory dis-
eases [1–8]. However, it is still unclear whether allogenic adult
SCs are rejected by the host immune system due to his-
toincompatibility [9] or resident SCs per se interfere with the
physiological function of the host immune system. Several SC
subtypes, including neural SCs [10] and mesenchymal stro-
mal cells (MSCs) [11–14], possess regenerative potential and
may interact with immune effector cells (IECs), profoundly
influencing their function in vitro and in vivo. The immune
system plays a critical role in the pathogenesis and progres-
sion of a number of degenerative diseases, raising the possi-
bility that SCs may be effective in repairing the damaged
organ by promoting cell formation and modulating the as-
sociated immune response [6,14–20]. Based on this premise,
the immunogenicity and immune modulatory properties of
SCs have to be carefully characterized to decipher their po-
tential clinical import. MSCs from the bone marrow (BM) and
adipose tissue (AT) have been well defined [21–27] and sim-
ilar immune regulatory functions have been identified in
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MSC-like SCs collected from Wharton’s jelly, amniotic fluid,
and placenta [28–30].
The immunosuppression induced by MSCs is not a direct
cellular effect but is mediated by a variety of inflammatory
cytokines released by the immune cells recruited to the in-
flammatory microenvironment [31]; they comprise interferon
(IFN)-g, tumor necrosis factor (TNF)-a, and interleukin (IL)-
1-a and -b. In response to these stimuli, MSCs migrate to the
site of injury, and become immune modulatory by affecting
inflammation and tissue repair in a positive manner. The
paracrine mechanisms underlying the impact of MSCs on the
local immune adaptation include a broad panel of molecular
pathways, such as IFN-g, IL-1b, transforming growth factor-
b, indoleamine-2,3-dioxygenase (IDO), IL-6, IL-10, prosta-
glandin-E2 (PGE2), hepatocyte growth factor, TNF-a, nitric
oxide (NO), heme oxygenase-1 (HO-1), HLA-G5 [21,22,31–
43], and others, some of which are still unknown.
Despite this extensive knowledge acquired on MSCs,
several types of adult and nonadult tissue-specific SCs have
been characterized, but whether or not these new SC cate-
gories exert an immune modulatory function comparable,
superior, or inferior to that of MSCs is an important un-
answered question. To test this hypothesis, we studied (1)
BM-MSCs [25]; (2) olfactory ectomesenchymal SCs (OE-
MSCs), which are distributed in the olfactory lamina propria
and induce neurogenesis, and restore the hippocampal
neuronal network [44–46]; (3) non-MSC leptomeningeal SCs
(LeSCs), described by us first in rats as nestin-positive cells
capable of differentiating into neuronal, astrocyte, and oli-
godendrocyte precursors [47,48] and, more recently, in mice
and humans (personal observation); and (4) human c-Kit-
positive SCs isolated from the amniotic fluid (AFSCs) [49],
from the adult heart (cardiac SCs: CSCs) [50–52]; and adult
lung SCs (LSCs) [53]. AFSCs are multipotent, nonteratogenic
cells with characteristics intermediate between embryonic
and adult SCs [49]. CSCs are multipotent cells capable of
differentiating into cardiomyocytes and coronary vessels
[50–52], while LSCs form lung structures of both endodermal
and mesodermal origin [53]. The standardized approach
previously introduced to characterize MSCs [25] was applied
to all SCs to define their immunological profile.
Materials and Methods
Isolation and culture of human SCs
BM-MSCs (five samples) were isolated from BM aspirates
of healthy donors (informed consent, approved by Ethical
Committee of Azienda Ospedaliera Universitaria Integrata
Verona; N. 1828, May 12, 2010- ‘‘Institution of cell and tissue
collection for biomedical research in Onco-Hematology’’). BM as-
pirates were cultured in 225-cm2 flasks at 5 · 105 nucleated
cells/cm2 concentration in alpha-minimal essential medium
(MEM), 10% heat-inactivated fetal bovine serum (FBS),
100U/mL penicillin, and 100 mg/mL streptomycin (all from
Gibco). After 72 h, nonadherent cells were removed and the
medium was replaced twice a week. Full characterization of
BM-MSCs has been already described by our group else-
where [22,26,28].
OE-MSCs (five samples) were obtained under a protocol
approved by the local ethical committee (Comite´ de Protec-
tion des Personnes) of Marseille. Informed consent was given
by each individual participating in the study, in accordance
with the Helsinki convention (1964) and French law relating
to biomedical research. OE-MSCs were purified as previ-
ously described [44]. Briefly, biopsies from the root of the
medial aspect of middle turbinate or the septum in dor-
somedial area were washed with Dulbecco modified Eagle
medium (DMEM)/HAM F12 and digested for 1 h with dis-
pase II solution (Boehringer). Then, the olfactory epithelium
was removed from underlying lamina propria, which was
cut into small pieces with 25-gauge needle. Tissue fragments
were incubated with collagenase 1A to complete the tissue
dissociation and, after centrifugation, the cell pellet was re-
suspended in a-MEM culture medium supplemented with
10% heat-inactivated adult bovine serum, 100U/mL peni-
cillin, and 100 mg/mL streptomycin (all from Gibco). Full
characterization of OE-MSCs has been already described by
our group elsewhere [44].
LeSCs (five samples) were obtained as previously described
[47] from human brain/spinal cord samples including lepto-
meninges collected during neurosurgical procedures (in-
formed consent, approved by Ethical Committee of Azienda
Ospedaliera Universitaria Integrata Verona; N. 1974, June 1,
201i—‘‘Institution of meningeal cell and tissue collection for bio-
medical research in regenerative medicine for neurodegenerative and
neurovascular diseases, and spinal cord injury’’). Leptomeninges
were detached from neural parenchyma, dissociated, and
washed with a-MEM; adherent cells were cultured in a-MEM,
10% heat-inactivated adult bovine serum, 100U/mL penicil-
lin, and 100mg/mL streptomycin (all from Gibco). Full char-
acterization of LeSCs has been already described by our group
elsewhere [47,48] and are part of another specific article.
AFSCs (six samples) were collected from confluent cul-
tures of adherent cells derived from human amniocentesis
carried out for diagnostic purposes (cytogenetic analysis),
after mother’s informed consent; cells were harvested and
immediately subjected to immunoselection [49]. Sorted c-Kit
positive AFSCs were grown in a-MEM medium (Gibco)
containing heat-inactivated adult bovine serum, 100U/mL
penicillin, and 100mg/mL streptomycin (all from Gibco),
supplemented with 18% Chang B and 2% Chang C (Irvine
Scientific). Full characterization of AFSCs has been already
described by our group elsewhere [49].
CSCs and LSCs (three samples each) were obtained from
enzymatic dissociation of myocardial and lung tissues, re-
spectively, and cultured as adherent cells as previously de-
scribed [50,53].
All SC types were detached (0.05% Tripsin-EDTA; Gibco)
and harvested when 80% confluent, and then either reseeded
at 103/cm2 concentration or frozen until use. All experiments
were performed between passages 2 and 6. Full character-
ization of CSCs and LSCs has been already described by our
group elsewhere [50,53].
Each SC type was characterized in terms of phenotype and
differentiation potential [22,44,50,53,54] following International
Society for Cellular Therapy (ISCT)-minimal criteria [55].
Immunofluorescence
SCs were harvested at 80% confluence and 2· 104 cells
were seeded on glass dishes pretreated with gelatin or poly-
d-lysine (Sigma Aldrich) in 24-well plates. After 24 h, cul-
tures were fixed with 4% paraformaldehyde and stained
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with appropriate antibody: mouse-anti-human CD73-PE (BD
Biosciences) for BM-MSCs, rabbit-anti-human nestin (Abcys)
for OE-MSCs, mouse-anti-human nestin (BD Biosciences)
for LeSCs, rabbit-anti-human c-Kit (DAKO) for AFSCs,
CSCs, and LSC; as secondary antibodies, goat-anti-rabbit-
AlexaFluor-549, goat-anti-mouse-AlexaFluor-488, and donkeyan-
ti-rabbit-FITC (all from Invitrogen) were used, respectively.
Hoechst-33342 or TOPRO-3 (Invitrogen) were added to reveal
nuclei. Images were obtained by fluorescence or confocal mi-
croscopy at 20·or 40·magnification.
Immunophenotyping
SCs at 80% confluence were stimulated or not for 40 h with
10 ng/mL IFN-g and 15ng/mL TNF-a (R&D Systems). The
lack of cytotoxic effects of this inflammatory cytokines was
previously confirmed [56]. Rested and primed SCs were
stained with the following monoclonal antibodies against
human markers: IgG1k-PE, CD54-PE, CD86-PE, CD106-PE,
CD200-PE, and HLA-ABC-PE all from BD Biosciences;
IgG1k-PE, CD80-PE, IgG1k-FITC, and HLA-DR-FITC all
from Beckman Coulter; IgG1k-PE, CD112-PE, CD155-PE,
IgG2b-PE, and CD274-PE all from Biolegend; IgG2a-PE,
unconjugated IgG2a, MICA/B-PE, ULBP-1-PE, ULBP-2-PE,
and unconjugated ULBP-3 all from R&D Systems, and goat-
anti-mouse-PE from DAKO.
For staining, 105 SCs were incubated with the selected
monoclonal antibody or appropriate isotype control in PBS
for 15min at room temperature. For ULBP-3 expression, PE-
conjugated goat anti-mouse IgG F(ab¢)2 was added, after
staining the cells with specific primary unconjugated anti-
body. According to manufacturer’s instruction, ULBP-1 ex-
pression was validated by intracellular staining using the
Cytofix/Cytoperm kit (BD Biosciences). Data were analyzed
by FACSCalibur and FACSCanto (BD Biosciences) and ex-
pressed as the ratio of geometric mean fluorescence intensity
(rMFI) obtained for each marker and its isotype-matched
negative control.
Evaluation of immunomodulation
and anti-apoptotic effects
IECs (CD3pos T cells, CD19pos B cells, and CD56pos NK cells)
were purified from peripheral blood using appropriate negative
selection kits (Miltenyi Biotec) with at least 95% cell purity, as
evaluated by flow cytometry. In each well, rested and primed
SCs were seeded with IECs at either 2·104 cell concentration
(high ratio, corresponding to a confluent monolayer), or 2·103
cell concentration (low ratio). After SC adhesion, 2·105 T cells,
2·104 B cells, or 2·104 NK cells previously stained with 5mM
carboxyfluorescein succinimidyl ester (Life Technologies) were
added. T cells were activated with 0.5mg/mL cross-linking anti-
CD3 and anti-CD28 antibodies (Sanquin) for 6 days in Roswell
Park Memorial Istitute (RPMI) supplemented with 10% human
AB serum. B cells were activated with 2mg/mL F(ab¢)2 anti-hu-
man IgM/IgA/IgG (Jackson Immunoresearch), 20 IU/mL
rhIL-2 (Proleukin; Novartis), 50 ng/mL polyhistidine-tagged
CD40 ligand, 5 mg/mL anti-polyhistidine antibody (R&D
Systems), and 2.5 mg/mL CpG B (Invivogen) for 4 days in
RPMI supplemented with 10% FBS (Invitrogen Life Technol-
ogies). NK cellswere activated by 100 IU/mL rhIL-2 for 6 days
in Iscove modified Dulbecco medium (IMDM) supplemented
with 10%humanAB serum. At the end of coculture, cells were
detached by trypsin and stained with PerCP mouse anti-hu-
man CD45 monoclonal antibody BD Biosciences and TO-
PRO-3 Iodide (Invitrogen Life Technologies); the
proliferation was assessed on viable TOPRO-3negCD45pos
cells by FACS analysis as the percentage of cells undergoing
at least one cell division. The proliferation rate was obtained
according to the following formula: (percentage of CD45pos
cell proliferation with SCs)/(percentage of CD45pos cell
proliferation without SCs)*100.
To evaluate the molecular pathways involved in immune
regulation, the following specific inhibitors were added to
SC/T cell cocultures: 1mM L-N-monomethylarginin (L-
NMMA)—inhibitor of inducible NO synthase (iNOS); 5 mM
NS-398 (Cayman Chemicals)—inhibitor of cyclooxygenase-2
(COX-2) that is necessary for PGE2 synthesis; 1mM L-1-
methyltryptophan (L-1MT)–IDO inhibitor (Sigma-Aldrich);
2mM tin-protoporphyrin (SnPP)—inhibitor of HO-1 (Frontier
Scientific); and 10mg/mL purified anti-human IFN-g NA/LE
mouse IgG1 (BD Biosciences).
To determine the IEC survival, primed and rested SCs were
seeded with IECs at the same ratios used for the immuno-
suppression assays. Cells were analyzed after either 4 days (B
and NK cells) or 6 days of coculture (T cells). Cells were then
harvested and stained with Allophycocyanin (APC) mouse
anti-human CD45 BD Biosciences and lymphocyte survival
was assessed following manufacturer’s instructions (PE active
caspase-3 apoptosis kit; BD Biosciences). Briefly, fixed and
permeabilized cells were stained with PE-anti-caspase-3 anti-
bodies and cell survival was assessed as percentage of active-
caspase-3negCD45pos viable cells by FACS analysis.
Immunogenicity assay
Resting and primed SC immunogenicity was evaluated in
a nonradioactive cytotoxicity assay using rh-IL-2 activated-
NK cells as effector cells, following manufacturer’s instruc-
tions (Delfia Cytotoxicity kit; Perkin Elmer). Briefly, SCs
were loaded with bis-acetoxymethyl terpyridine dicarbox-
ylate (BATDA) fluorescent dye and then incubated for 3 h
with various ratios of allogeneic NK cells preactivated for
48 h with 100 IU/mL rhIL-2. Cytotoxicity was quantified by
assessing fluorescence release in coculture supernatants by a
time-resolved fluorimeter (VictorX4, Perkin Elmer).
Bioinformatics
Hierarchical cluster analysis of protein expression was
used to group SCs with similar expression pattern. Molecular
markers with differential expression pattern among various
SC types were selected from the rMFI derived from im-
munophenotyping. The expression data were logarithm
transformed and grouped using hierarchical clustering al-
gorithm in Gene Cluster 3.0 program [57]. Heat-map was
performed using Java Treeview program [58].
Statistical analysis
Data were expressed as mean – standard deviation, except
for immunophenotype data that were expressed as
mean– standard error of the mean. Statistical analysis was
performed by Prism software (GraphPad) using the Wil-
coxon test to compare the effect of priming on the same
IMMUNOLOGICAL PROPERTIES OF STEM CELLS 3
SCs, while one-way ANOVA test was used to assess the
differences among SCs types. P < 0.05 was considered sta-
tistically significant.
Results
IFN-c and TNF-a strongly regulate SC
immunophenotype
Previous reports have highlighted the differences among the
SC types employed in this study in terms of marker expression,
morphology (Fig. 1), differentiation potential, in vivo engraft-
ment, and regenerative capabilities. The immunophenotype of
resting and IFN-g- and TNF-a-primed BM-MSCs, OE-MSCs,
LeSCs, AFSCs, CSCs, and LSCs was studied in parallel (Table 1
and Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub
.com/scd), also by using a hierarchical cluster analysis (Fig. 2).
These SC types expressed HLA-ABC molecules at different
levels. At baseline, HLA-ABC molecules were more abundant
in OE-MSCs and LeSCs than in BM-MSCs, AFSCs, CSCs, and
LSCs; however, following inflammatory priming, HLA-ABC
molecules increased in all SC categories, and significant chan-
ges occurred in LeSCs (2.6-fold), AFSCs (2.2-fold), CSCs (2.0-
fold), and LSCs (3.2-fold). In control conditions, HLA-DR was
scarcely or partially expressed by BM-MSCs, but after inflam-
matory priming, it dramatically increased in BM-MSCs, OE-
MSCs, and LSCs; low levels of HLA-DR were detected in
primed AFSCs, LeSCs, and CSCs. The costimulatory molecules
CD80 and CD86 were undetectable in all SC types with the
exception of resting CSCs; however, CD86 was no longer de-
tectable in CSCs after inflammatory priming. CD40 was weakly
expressed in resting OE-MSCs and AFSCs, but a significant
increase in CD40 was observed after inflammatory priming in
BM-MSCs (3.2-fold), OE-MSCs (2.0-fold), and LeSCs (3.8-fold).
Primed AFSCs did not upregulate CD40, and CSCs and LSCs
never expressed this marker.
Two adhesion molecules CD54 (ICAM-1) and CD106
(VCAM-1), which are involved in cell migration and inter-
action between MSCs and inflammatory cells [59–61], were
tested. CD54 was highly expressed in OE-MSCs, and low
levels of this molecule were detected in the other SCs. CD54
was markedly upregulated in all primed SC types (BM-
MSCs, 174.6-fold, OE-MSCs, 39.6-fold, LeSCs, 112.0-fold,
AFSCs, 44.7-fold, CSCs, 47.0-fold, and LSCs, 129.0-fold).
CSCs and LSCs did not express CD106 at baseline, and only
primed CSCs showed CD106 weakly. Conversely, BM-
MSCs, OE-MSCs, LeSCs, and AFSCs constitutively ex-
pressed CD106, which was significantly upregulated after
priming (BM-MSCs, 4.3-fold, OE-MSCs, 2.0-fold, LeSCs,
12.0-fold, and AFSCs, 14.0-fold).
CD200 and CD274 (PD-L1) modulate the immune re-
sponse via a cell-to-cell contact-dependent mechanism [62–
64]. CD200 was highly expressed in CSCs, modestly present
in BM-MSCs and OE-MSCs, and absent in AFSCs, LeSCs,
and LSCs. After inflammatory priming, a 2.7-fold down-
regulation of CD200 occurred in CSCs while no changes
were observed in the other SCs. At baseline, CD274 was
constitutively expressed in all SCs but mostly in OE-MSCs
and AFSCs. Inflammatory priming resulted in a proportional
upregulation of CD274 in the various SC categories.
The NK cell-activating ligands were evaluated [27,65].
CD112 (nectin-2) and CD155 Poliovirus receptor (PVR),
which stimulate the DNAX Accessory Molecule-1 (DNAM-1)
receptor, were expressed at high levels in all SCs at baseline.
Inflammatory priming increased by *2-fold the expression
FIG. 1. Representative immunofluorescence staining of various human stem cell (SC) types. (A) Bone marrow (BM)-
mesenchymal stromal cells (MSCs) were stained with anti-CD73-PE (red) and TOPRO-3 (blue); (B) olfactory ectomesenchymal
SCs (OE-MSCs) were stained with anti-Nestin (green) and Hoechst-33342 (blue); (C) leptomeningeal SCs (LeSCs) were stained
with anti-Nestin (red) and TOPRO-3 (blue); (D) amniotic fluid SCs (AFSCs) were stained with anti-c-Kit (green) and TOPRO-3
(blue); (E) cardiac SC (CSCs) were stained with anti-c-Kit (white) and TOPRO-3; (F) lung SCs (LSCs) were stained with anti-c-
Kit (green) and TOPRO-3 (blue). Scale bars: 50mm (A–C); 20mm (D–F).
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of CD112 and CD155 in all SCs but CSCs and LSCs. In the
latter two cases, priming did not alter the levels of CD112
and CD155. The ligands of the NKG2D receptor, MICA/B
and ULBPs, were then examined. ULBP-1, ULBP-2, ULBP-3,
and MICA/B were not particularly abundant at rest-
ing conditions and after inflammatory priming in all SC
populations.
Overall, the immunophenotype observed at resting and
inflammatory conditions show many similarities among
different SC types; moreover, the clustering analysis high-
lighted a clear distinction between resting and primed SCs,
which suggests a common pattern of protein modulation
induced by inflammatory mileu (Fig. 2). These data are in
agreement with defective antigen-presenting cell functions
(expression of HLA class I and class II molecules without co-
expression of costimulatory molecules) and activating capa-
bility toward NK cells due to the partial expression of NK
cell-activating receptors possibly leading to SC rejection;
nevertheless, the latter activity may be counterbalanced fol-
lowing inflammatory priming by the upregulation of HLA
class I molecules triggering inhibitory NK receptors.
SCs share immunomodulatory properties
MSCs from several organs exert comparable regulatory
effects on cells belonging to the innate and acquired immu-
nity. Thus, we determined whether the variety of SC types
included in the current study possessed similar immuno-
logical properties. Resting or primed SCs were cocultured
with purified T-, NK-, and B cells to evaluate their ability to
induce proliferation of unstimulated IECs. All SC types
neither activated nor promoted IEC growth (data not
shown). Then, the role of SCs in IEC replication was assessed
by using different IEC:SC ratios, which ranged from 10:1
(high ratio) to 100:1 (low ratio) for T cells, and from 1:1 (high
ratio) to 10:1 (low ratio) for NK and B cells, according to the
standardized approach previously used with BM-MSCs [25].
At resting and primed conditions, none of the SC types
Table 1. Expression of Different Markers on Various Human SCs in Resting and Primed Conditions
Marker/SCs BM-MSC OE-MSC LeSC AFS CSC LSC
Immunological
HLA-ABC 16.97– 2.48 29.42– 5.46 22.83– 4.32 11.29 – 2.98 5.15 – 0.17 2.74 – 0.1
27.37– 6.1 35.4 – 5.47 59.34– 10.2** 25.3 – 3.82** 10.37– 0.66* 8.7 – 0.6*
HLA-DR 1.42 – 0.21 1 – 0 1.04 – 0.04 1.02 – 0.02 1– 0 1.1 – 0.04
21.91– 3.61** 15.04– 2.56* 1.58 – 0.17 2.66 – 0.91 3.53 – 0.1** 12.06– 0.3**
CD40 1.29 – 0.14 1.93 – 0.17 1.19 – 0.12 2.1 – 0.26 1– 0 1– 0
4.14 – 0.74* 3.8 – 0.27** 4.55 – 0.66* 2.4 – 0.07 1– 0 1– 0
CD80 1– 0 1 – 0 1 – 0 1 – 0 1– 0 1– 0
1.36 – 0.04 1 – 0 1 – 0 1 – 0 1– 0 1.07 – 0.06
CD86 1.24 – 0.07 1.09 – 0.09 1.11 – 0.05 1.26 – 0.16 2.2 – 0.15 1– 0
1.02 – 0.02 1.34 – 0.31 1.18 – 0.18 1.17 – 0.09 1.06 – 0.05* 1– 0
Adhesion proteins
CD54 6.83 – 2.68 35.28– 6.51 9.67 – 1.2 14.04 – 4.78 4.43 – 0.9 2.1 – 0.14
1193 – 98** 1400 – 156*** 1082 – 101** 626 – 60.9*** 208– 14.54** 271– 13.5**
CD106 5.8 – 2.08 6.11 – 1.54 2.06 – 0.19 1.89 – 0.27 1– 0 1– 0
25.3 – 10.62 12.47– 4.62 25 – 5.12* 26.58 – 7.3* 1.57 – 0.07* 5.16 – 0.4*
Immunomodulatorry
CD200 3.47 – 1.56 2.82 – 0.76 1.06 – 0.02 1.17 – 0.06 17.24– 6.64 1– 0
3.73 – 1.06 1.86 – 0.45 1.15 – 0.12 1.18 – 0.1 6.03 – 0.42 1– 0
PD-L1 5.28 – 0.55 15.68– 2.68 2.17 – 0.14 23.88 – 4.2 3.72 – 0.21 4.37 – 0.1
76.14– 6.65** 96.42– 26.51* 60.45– 17.3* 80.2 – 12.7** 12.63– 0.38*** 8.4 – 1.17**
NK ligands
CD112 11.87– 2 30.86– 4.75 12.5 – 4.33 23.7 – 1.37 7.18 – 1.21 4.95 – 0.26
26.45– 5.67* 62.38– 8.78** 27.87– 5.07** 33.8 – 4.2 5.23 – 0.02 3.54 – 0.16
CD155 17.9 – 3.78 57.86– 12.8 57.82– 20.35 78.48 – 17.9 7.9 – 1.47 6.23 – 0.44
29.48– 7.84 128.5– 31 103.8– 12* 102.7 – 13.04 6.88 – 0.04 8.2 – 0.3
MICA/B 1.7 – 0.24 1.19 – 0.17 1.07 – 0.08 1.75 – 0.4 1.57 – 0.06 1.15 – 0.02
1.16 – 0.1 1.06 – 0.06 1 – 0 1.43 – 0.36 1.03 – 0.03 1.18 – 0.08
ULBP-1 1.79 – 0.21 1.43 – 0.08 1.43 – 0.04 1.23 – 0.02 1.14 – 0.06 1– 0
1.67 – 0.27 1.58 – 0.13 1.47 – 0.16 1.46 – 0.1 1.31 – 0.06 1– 0
ULBP-2 3.73 – 1.8 2.47 – 0.28 2.31 – 0.45 3.12 – 0.55 3.84 – 0.02 1.4 – 0.01
3.04 – 0.66 1.54 – 0.23* 2 – 0.3 1.88 – 0.23* 2.38 – 0.08 1.12 – 0.06
ULBP-3 2.3 – 1.04 1.3 – 0.27 1.16 – 0.12 1.64 – 0.59 2.2 – 0.07 3.24 – 0
1.35 – 0.2 1.15 – 0.1 1.54 – 0.46 2.38 – 0.68 2.6 – 0.11* 1.04 – 0.03***
Cells were cultured for 48 h under normal or inflammatory conditions, stained with different antibodies and analyzed by flow cytometry.
Data are presented as mean – SEM of relative Mean Fluorescence Intensity (rMFI) of five (BM-MSCs, OE-MSCs, AFSCs, and LeSCs) or three
(CSCs, LSCs) different experiments derived from resting (upper) and primed (below) SCs for each marker.
*P< 0.05, **P< 0.01, ***P< 0.001.
SC, stem cell; BM-MSC, bone marrow-mesenchymal stromal cells; OE-MSC, olfactory ectomesenchymal SCs; LeSC, leptomeningeal SCs;
AFS, amniotic fluid SCs; CSC, cardiac SCs; LSC, lung SCs.
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displayed a modulatory function on IECs at low ratios (data
not shown). Conversely, at high ratios, all SCs inhibited T
cell division at resting conditions, and significantly more
following pretreatment with inflammatory cytokines (Fig.
3A). OE-MSCs, LeSCs, CSCs, and LSCs showed a greater
immunomodulatory effect than AFSCs and BM-MSCs.
All SCs with the exception of LeSCs displayed inhibitory
properties on NK cells in absence of pretreatment with IFN-g
and TNF-a (Fig. 3B). Resting and primed OE-MSCs inhibited
proliferation of NK cells by more than 90%. Resting LSCs
and CSCs had an intermediate effect on NK cell proliferation,
and BM-MSCs and AFSCs had the lowest. Primed BM-MSCs
had a partial enhanced immunosuppressive activity, a re-
sponse that was not detected in AFSCs, LSCs, and CSCs.
LeSCs had no effect at baseline but, following priming,
manifested a strong immunodulatory function comparable
to OE-MSCs, and higher than BM-MSCs.
In the absence of inflammatory stimuli, MSCs cannot in-
hibit B cell growth due to the lack of IFN-g release [22].
Although resting LSCs enhanced B cell proliferation, the
other resting SC types failed to demonstrate any immuno-
modulatory function on B cells (Fig. 3C). However, primed
SCs inhibited B cell replication. OE-MSCs and LeSCs showed
an effect that was significantly greater than in the other SCs
including BM-MSCs. Collectively, distinct SC categories
possess common immunomodulatory properties, which at
times differ qualitative and quantitatively (Table 2).
Molecular pathway in SC-mediated
immunomodulation
To dissect the mechanisms responsible for the impact of
SCs on T cell division, specific inhibitors (L-1MT, LNMMA,
NS-398, and snPP) were added to SC-T cell cultures at doses
FIG. 2. Hierarchical cluster anal-
ysis of protein expression of various
human SCs in resting and primed
conditions. Modulation of expres-
sion of fifteen proteins in resting
and inflammatory-primed condi-
tions. Heat map showed the down-
(green) or upregulation (red) of
protein expression. Different sam-
ples were grouped using hierarchi-
cal clustering algorithm.
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that did not alter T cell viability and growth. The neutraliz-
ing anti-IFN-g monoclonal antibody was also used to define
the role of this cytokine in immune modulation. With the
exception of resting OE-MSCs, L-1MT completely rescued T
cell proliferation in the presence of resting or primed SCs;
this result indicates that IDO is a major determinant of the
anti-proliferative effects that SCs have on T cells (Fig. 4).
Conversely, inhibitors COX-2 (NS-398), HO-1 (snPP), and
IFN-g blocking antibody only partly restored T cell replica-
tion. The iNOS inhibitor LNMMA, however, failed to restore
T cell division in the presence of either resting or primed
human SCs (data not shown). NS-398 interfered with PGE2
synthesis attenuating the effects of resting LeSCs and primed
BM-MSCs. Interestingly, snPP-mediated HO-1 inhibition
modestly reactivated CSC-induced T cell suppression.
Collectively, our observations suggest that the anti-pro-
liferative effects of SC types on T cells is predominantly
driven by the activation of IDO and the degradation of
tryptophan (Table 2), an essential factor for T cell division
and the generation of kynurenine, a critical immunomodu-
latory molecule.
Inflammatory priming, SC immunogenicity,
and NK-mediated lysis
Treatment of BM-MSCs with inflammatory cytokines re-
duces the susceptibility of these cells to NK cell-mediated
lysis [27]. This phenomenon is initiated by the expression in
BM-MSCs of surface molecules, induced by the inflamma-
tory milieu, which have the ability to activate or inhibit NK
receptors [65,66]. These ligands, including CD112, CD155,
MICA/B, ULBPs, and HLA class I and II molecules, are
present in the SC types studied here (Table 1). To assess
whether SCs are sensitive to NK cell-mediated cytotoxicity,
BATDA stained-SCs were cocultured with different ratios of
IL-2-stimulated NK cells. Cytotoxicity activity was measured
by the quantity of BATDA released in the medium that is
proportional to NK cell-mediated lysis. NK cells were capa-
ble of partially lysing resting SCs, and this effect was directly
proportional to the increase of NK/SC ratio (Fig. 5 and Table
2). However, an opposite effect was observed when SCs
were pretreated with IFN-g and TNF-a; SCs were signifi-
cantly less vulnerable, suggesting that the differential ex-
pression of surface molecules attenuates the susceptibility of
SCs to NK-mediated lysis.
SC and lymphocyte survival
Resting MSCs prevent T cell apoptosis promoted by the
engagement of T cell receptors [67]. On the basis of these
observations, we tested whether different SC types were
capable of protecting IEC survival and whether this effect
was modulated by inflammatory priming. Unstimulated T,
NK, and B cells were cultured alone or in presence of either
resting or primed SCs at different ratios. After 4 days (B and
NK cells) and 6 days (T cells), cocultured cells were har-
vested and stained with anti-active-caspase 3 antibody, and
analyzed by flow cytometry. Resting and primed SCs sig-
nificantly reduced IEC apoptosis (Fig. 6). This phenomenon
was less apparent in T cells, possibly due to the higher sur-
vival of this cell type with respect to B and NK cells. We also
found a dose-dependent anti-apoptotic effect of BM-MSCs,
OE-MSCs, and LeSCs on B cells.
Discussion
Cell loss, inflammation, immune system activation, and
cell renewal occur following tissue injury. Alterations in this
sequence of events result in inadequate organ repair giving
rise to pathologic states [11,19,68,69]. Inflammatory priming
has been viewed as a requirement for MSCs to have immune
modulatory properties in vitro and in vivo [4–6,11–14]. The
origin of MSCs, the secretion of soluble factors conferring
proper SC licensing, and the level of inflammation at the site
of cell delivery may account for some of the differences
FIG. 3. Human SC inhibitory effect on stimulated immune
effector cell (IEC) proliferation. Human IEC (ie, T, NK, and B
cells) were stimulated with specific stimuli and cultured
alone (dark gray bars) or in the presence of resting (white bars)
or primed (light gray bars) allogeneic human SCs. At the end
of coculture, lymphocyte proliferation was assessed using
carboxyfluorescein succinimidyl ester (CFSE) dilution
method, as described in Materials and Methods section.
CFSE fluorescence was analyzed after 7 days for T (at 10:1
T/SC ratio) and NK (at 1:1 NK/SC ratio) cells (A and B,
respectively), while for B cells (C) the fluorescence was de-
tected after 4 days of coculture (at 1:1 B/SCs ratio). The
results are expressed as relative proliferation percentage of
IEC, normalized to IEC cultured alone (100%). Error bars
represented mean– SD of five independent experiments for
BM-MSCs, OE-MSCs, LeSCs, and AFSCs and three inde-
pendent experiments for CSCs and LSCs. *P < 0.05, **P < 0.01,
***P < 0.001.
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Table 2. Summary of Immunological Effects of Human SCs of Various Origin
Immune modulatory effect Molecular mechanism Immunogenicity
SC Types/IEC T NK B T NK
BM-MSC + + x IDO ***
pBM-MSC + + + + + IDO *
OE-MSC + + + + + - // ***
pOE-MSC + + + + + + + + IDO *
LeSC + + + x - IDO/COX-2 ***
pLeSC + + + + + + + + + IDO *
AFS + x x IDO/IFN-g ***
pAFS + + x + IDO/IFN-g *
CSC + + + + - IDO/HO-1 ***
pCSC + + + + + + IDO **
LSC + + + + - IDO ***
pLSC + + + + + + + IDO **
Inhibition range (%) Symbol
supportive effect -
0–20 x
20–50 +
50–75 + +
> 75 + + +
Susceptibility to NK-mediated lysis (%) Symbol
0–30 *
30–50 **
> 50 ***
Results derived from immunomodulatory and immunogenicity assays are summarized to compare different SC type behavior; p:
inflammatory primed. For immunogenicity assay, NK:SC ratio is 25:1
FIG. 4. Effect of specific inhibitors on T cell proliferation. Human purified T cells were stained with CFSE, stimulated with
mitogenic anti-CD3 and anti-CD28 antibodies, and cultured alone or in presence of different resting and primed SC types (at
10:1 T/SCs ratio). In each coculture the following inhibitors (I) were added: L-1MT (A), Anti-IFN-g (B), NS-398 (C), and snPP
(D). After 6 days, cells were harvested and T cell proliferation was evaluated by FACS analysis. The results are expressed as
relative proliferation percentage of T cells, normalized to T cells cultured alone (100%). Error bars represented mean – SD of
five independent experiments for BM-MSCs, OE-MSCs, LeSCs, and AFSCs and three independent experiments for CSCs and
LSCs. *P < 0.05, **P < 0.01, ***P < 0.001.
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reported in the literature [12]. However, the immune mod-
ulatory function of BM-MSCs has been documented in graft-
versus-host disease [4–6], autoimmune encephalomyelitis
[17], sepsis [3], collagen-induced arthritis, and bowel in-
flammation [15,16,20]. But whether other SC categories have
the ability to exert comparable effects was unknown and our
results provide novel information supporting the view that a
variety of SCs share the critical aspect of being immune
privileged.
An important distinction has to be emphasized among the
SC types analyzed here. It is generally considered that the
regenerative potential of transplanted SCs may be exerted
either directly, through the engraftment of SCs inside the
damaged tissue followed by proliferation and differentia-
tion into novel terminally differentiated cell progeny, or in-
directly, through the release of soluble factors favoring
the healing processes mediated by resident SCs and con-
trasting the negative effect of inflammatory phenomena. The
FIG. 5. Immunogenicity of resting and primed human SCs. To evaluate NK cytotoxicity, SCs were labeled with BATDA (as
reported in Materials and Methods section) and then used as effector cells in coculture with IL-2-stimulated NK cells at
different NK/SC ratios. The amount of cytotoxicity was calculated as release of fluorescence by lysed SCs, and detected by
time-resolved fluorimeter (Victor X4 Multilabel Plate Reader, PerkinElmer). Each graphic shows the results obtained from
five independent experiments, in which resting (solid line) and primed (dashed line) SCs were used as target cells. Data are
expressed as percentage of fluorescence release. Error bars represented mean – SD of five independent experiments for BM-
MSCs, OE-MSCs, LeSCs, and AFSCs and three independent experiments for CSCs and LSCs. *P < 0.05, **P < 0.01, ***P < 0.001.
BATDA, bis-acetoxymethyl terpyridine dicarboxylate.
FIG. 6. Trophic support of resting and primed human SCs on different immune effectors. Resting and primed SCs were
cocultured with unstimulated human IECs (ie, T, B, and NK cells). At the end of coculture, immune cell survival was detected
by measuring cytosolic active-caspase-3 (as reported in Materials and Methods section). The results are expressed as per-
centage of caspase-3negCD45pos cells, and the analysis was performed by flow cytometry. Error bars represented mean – SD of
five independent experiments for BM-MSCs, OE-MSCs, LeSCs, and AFSCs and three independent experiments for CSCs and
LSCs. *P < 0.05, **P < 0.01, ***P < 0.001.
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predominant therapeutic efficacy of MSCs and MSC-like SCs
is mediated via a paracrine mechanism associated with the
release of several cytokines that profoundly influence the
response of IECs [22,31,34,36–38,40,43]. This principle ap-
plies to all SCs that modulate inflammation and have a
limited capacity to generate a specialized progeny. However,
they indirectly activate resident SCs, enhancing the repair of
the organ [70–72]. Because of these characteristics, thera-
peutically, MSCs and MSC-like SCs may have to be repeat-
edly employed to exert their role long-term, in absence of
clear evidence of their homing and persistence inside the
tissues [14–20]. Conversely, the delivery of tissue-specific
multipotent adult SCs, such as CSCs and LSCs, to the cor-
responding damaged organ fails to stimulate the resident
SCs nested in proximity to or distant from the injured pa-
renchyma [73,74]. Their exclusive beneficial effect is linked to
their engraftment, expansion, and ultimately the regenera-
tion of functionally-competent cells and vessels [50,53]. Thus,
two important aspects have to be discussed. First, the rec-
ognition obtained in the current study in vitro that CSCs and
LSCs interfere with the inflammatory microenvironment is
strongly consistent with their inherent ability to home to and
divide within the damaged tissue, which has been previ-
ously demonstrated experimentally [53,73,74], in absence of
inflammation in the parenchyma surrounding the integrated
SCs shortly after their administration, or chronically in the
regions adjacent to the regenerated myocardium, or lung
structures. In other words, our data suggest that the immune
modulatory properties of CSCs and LSCs here described in
vitro for the first time may have a role in vivo in favoring
their regenerative potential. Secondly, both CSCs and LSCs
become structurally and functionally coupled with the cells
of the recipient organ, creating new niches in which the SCs
can divide asymmetrically [73,75,76], thus ensuring the
preservation of the SC pool and the formation of parenchy-
mal and vascular cells [50,53,77]. It is likely that the potential
clinical implementation of these SC populations is signifi-
cantly strengthened by their immunomodulatory function. In
vivo studies with each SC type are mandatory to assess the
role of these immunological features in SC engraftment and
regenerative potential. Similarly, further in vivo studies in
animal models will clarify whether these considerations on
CSCs and LSCs may be applied also to other c-Kit-positive
SC populations, such as AFSCs [49], or to non-MSC SCs with
in vitro and in vivo neurogenic potential, such as OE-MSCs
[44–46] and LeSCs [47,48].
As far as the general features related to the acquisition of
the immune regulatory functions are concerned, the im-
munophenotype of the different SCs revealed a common
switch, in response to inflammatory priming, from a resting
to an activated immunosuppressive pattern. This change
included the upregulation of MHC class I, the adhesion
molecules ICAM-1 and VCAM-1, and the immunosuppres-
sive molecule PD-L1 (CD274). Importantly, ICAM-1, VCAM-
1, and PD-L1 strongly bind to IECs promoting cell-to-cell
contact and exposing immune cells to immunosuppressive
molecules [61–63]. A de novo expression of MHC class II was
detected and, although this adaptation may theoretically
favor an immune cell response, lymphocyte activation was
never detected when cocultured with the variety of SC types
investigated here. This result may reflect the absent or weak
expression of the co-stimulatory molecules CD80 and CD86.
Our observations indicate that resting and primed SCs
enhance the viability of unstimulated IECs rather than in-
hibiting their function. All SC types show an anti-apoptotic
effect on T, B, and NK cells, suggesting that their potential
inhibitory role [12,22] is not a constitutive property of SCs,
but is acquired through IEC activation. If SCs are not in-
flammatory-primed and are challenged with activated NK
cells, the resulting interaction is SC lysis. However, IFN-g
and TNF-a licensing makes SCs resistant to NK cells, a
characteristic particularly apparent for B cell proliferation. A
similar requirement has previously been shown for MSCs
[27].
Here, we found that the exposure to inflammatory milieu
leads to IDO activation that becomes the central immuno-
suppressive enzyme affecting T cell proliferation in all SC
types, as shown previously also by other authors [36,38],
even if some other molecules may be involved. The dis-
crepancies among different published data could be related
to different experimental approaches; thus, method and as-
say standardization is required to obtain comparable results,
as suggested by ISCT MSC Committee [78].
In summary, our findings have provided new information
concerning the immune modulatory properties of several SC
types, an attribute that was previously unknown. It is now
clear that immunomodulation is not a peculiar feature of
MSC-like cells, but actually a general property of SCs that
may be induced or enhanced by inflammatory stimuli. SC
niches may be viewed as immunological structures playing a
fundamental role in tissue homeostasis, by regulating the
interplay of SCs and IECs, which promotes cell survival.
With persistent antigen activation and immune responses,
the immunological SC niche may become an important
variable of the pathogenesis and progression of degenerative
diseases. Understanding these mechanisms may help iden-
tifying novel therapeutic strategies or recognizing the most
effective SC class able to interfere with damage-mediated
inflammation, and to induce tissue regeneration and organ
repair.
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